Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

The main goal of this study is to look at the effectiveness and anti-tumor activity (preventing growth of the tumor) of the drugs niraparib and ipilimumab, on the patients and their pancreatic cancer. This study will involve two different treatment arms. In Arm A, patients will receive niraparib plus ipilimumab. In Arm B, patients will receive standard chemotherapy. The main questions the study aims to answer are: * Does niraparib plus ipilimumab slow down tumor growth in patients with pancreatic cancer? * What medical problems do participants have when taking niraparib plus ipilimumab? Par

Trial Details

NCT ID
NCT06747845
Phase
PHASE2
Sponsor
Abramson Cancer Center at Penn Medicine
Status
RECRUITING
Cancer Type
Pancreatic Ductal Adenocarcinoma Pancreatic Cancer
Interventions
  • Niraparib
  • FOLFIRI
  • Ipilimumab
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

  • Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma with metastatic disease
  • ≥18 years of age
  • Patients must be able to understand the study procedures and agree to participate in the study by providing written informed consent
  • Participants must have received 8-12 cycles (4-6 months) of first-line FOLFIRINOX or modified FOLFIRINOX for metastatic disease with stable disease…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Trials on Trialify →